Wednesday, February 10, 2010, 3:42pm SGT - The Singapore stock market closes in 1 hour and 18 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEFINANCE NEWS
    Market:       |  

Enzo Biochem Inc. (ENZ)

At 5:02AM SGT: 4.81 USD  Up 0.05 (1.05%)  
 MORE ON ENZ 
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials
ProfileGet Profile for:
Enzo Biochem Inc.
527 Madison Avenue
New York, NY 10022
Phone: 212-583-0100
Fax: 212-583-0150
Web Site: http://www.enzo.com

 DETAILS 
Index Membership:S&P 600 SmallCap
S&P 1500 Super Comp
Sector:Healthcare
Industry:Medical Laboratories & Research
Employees (last reported count):539

 REUTERS ABRIDGED BUSINESS SUMMARY 
Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.
Key Statistics
More from Reuters
Expanded Business Description

 COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Enzo Biochem Inc.


    More from Reuters
    Reuters offers more in-depth Company Research , Stock Screening , and >Risk Alerts on over 10,000 U.S. Equities.

     REUTERS ABRIDGED FINANCIAL SUMMARY 
    View Financials
    More from Reuters
    Significant Developments - Highlights - Performance - Ratio Comparison


     OFFICERS 
     PayExercised
    Dr. Elazar Rabbani Ph.D., 66
    Co-Founder, Chairman, Chief Exec. Officer and Sec.
    $ 999.00K $ 352.00K
    Mr. Barry Weiner , 60
    Co Founder, Pres, Chief Financial Officer, Principal Accounting Officer, Treasurer
    $ 814.00K $ 352.00K
    Mr. Shahram K. Rabbani , 58
    Co Founder
    $ 295.00K $ 352.00K
    Dr. Carl W. Balezentis Ph.D., 52
    Pres of Enzo Life Sciences Inc
    $ 310.00K $ 0
    Dr. Kevin Krenitsky M.D., 44
    Pres of Enzo Clinical Labs Inc
    $ 92.00K $ 0
    Dollar amounts are as of 31-Dec-09 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders
    More from Reuters:
    Full List - Bios - Compensation - Options


    Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
    Get Profile for Another Symbol:
    Search by Company
    Latest NewsSingapore Indices